Q3 EPS Estimates for Xeris Biopharma Reduced by Analyst

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Stock analysts at Leerink Partnrs reduced their Q3 2025 earnings estimates for Xeris Biopharma in a research note issued on Wednesday, June 4th. Leerink Partnrs analyst R. Ruiz now forecasts that the company will earn $0.02 per share for the quarter, down from their previous estimate of $0.03. The consensus estimate for Xeris Biopharma's current full-year earnings is ($0.41) per share. Leerink Partnrs also issued estimates for Xeris Biopharma's Q4 2025 earnings at $0.01 EPS and FY2028 earnings at $0.50 EPS.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. The firm had revenue of $57.80 million for the quarter, compared to the consensus estimate of $57.61 million.

Several other research firms have also recently weighed in on XERS. Craig Hallum upped their price objective on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a "buy" rating in a research report on Friday, March 7th. Piper Sandler reissued a "neutral" rating and issued a $4.00 target price (up previously from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Leerink Partners increased their target price on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a report on Friday, March 7th. Wall Street Zen cut shares of Xeris Biopharma from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, HC Wainwright reissued a "buy" rating and issued a $8.00 target price (up previously from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Xeris Biopharma currently has an average rating of "Moderate Buy" and an average price target of $6.25.

Xeris Biopharma Price Performance

XERS traded down $0.10 on Friday, hitting $4.48. 1,964,520 shares of the stock were exchanged, compared to its average volume of 1,973,095. Xeris Biopharma has a 12 month low of $2.03 and a 12 month high of $6.07. The business has a 50-day moving average of $4.56 and a two-hundred day moving average of $4.09. The firm has a market capitalization of $700.60 million, a price-to-earnings ratio of -9.96 and a beta of 0.71.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. R Squared Ltd increased its position in Xeris Biopharma by 27.7% during the 1st quarter. R Squared Ltd now owns 15,730 shares of the company's stock valued at $86,000 after purchasing an additional 3,410 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Xeris Biopharma by 4.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,388 shares of the company's stock valued at $273,000 after purchasing an additional 3,447 shares during the period. Wealth Enhancement Advisory Services LLC increased its position in Xeris Biopharma by 31.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 16,268 shares of the company's stock valued at $55,000 after purchasing an additional 3,847 shares during the period. Apollon Wealth Management LLC increased its position in Xeris Biopharma by 19.8% during the 1st quarter. Apollon Wealth Management LLC now owns 24,160 shares of the company's stock valued at $133,000 after purchasing an additional 4,000 shares during the period. Finally, Janney Montgomery Scott LLC increased its position in Xeris Biopharma by 31.4% during the 4th quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company's stock valued at $78,000 after purchasing an additional 5,500 shares during the period. Institutional investors own 42.75% of the company's stock.

Insider Activity at Xeris Biopharma

In related news, insider Beth Hecht sold 40,000 shares of the firm's stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $5.43, for a total value of $217,200.00. Following the completion of the transaction, the insider now owns 1,353,510 shares in the company, valued at $7,349,559.30. This trade represents a 2.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.47% of the stock is owned by company insiders.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.